|drug1899||Lung CT Wiki||1.00|
|drug686||Camostat Mesilate Wiki||0.32|
|D007251||Influenza, Human NIH||0.29|
|D055370||Lung Injury NIH||0.18|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.
Description: Proportion of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes.Measure: Clinical Deterioration Time: 14 days
Description: The change in (clearance of) viral RNA will be measured by PCR testing at days 1, 14, 28, and 40 days.Measure: Change in Viral Load Time: 40 days
Description: Percentage of patients that experience severe respiratory or other organ failure.Measure: Rate of Organ Failure Time: 28 days
Description: Percentage of patients requiring ICU admission or ventilation.Measure: Progression to ICU Care or Ventilation Time: 28 days
Description: Clinical status will be assessed using the COVID 7-Point Ordinal Outcomes Scale. This scale ranges from 1-7. Lower scores indicate worse outcomes; higher scores indicate fewer symptoms and better outcomes.Measure: Change in Clinical Status Time: 14 days
Description: Percentage of patients who have died by day 14.Measure: Mortality Time: 14 days
Description: Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events.Measure: Rate of severe adverse events Time: 14 days
Description: Number of days patients do not require oxygen supplementation.Measure: Oxygen-free days Time: 28 days
Description: Number of days patients do not require mechanical ventilation.Measure: Ventilator-free days Time: 28 days
Description: Number of days patients do not require vasopressor treatment.Measure: Vasopressor-free days Time: 28 days
Description: Number of days patients do not require ICU services.Measure: ICU-free days Time: 28 days
Description: Number of days patients do not require hospitalization.Measure: Hospital-free days Time: 28 days
Description: Proportion of patients meeting Hy's law criteria.Measure: Patients meeting Hy's Law criteria Time: 28 days
Description: Proportion of patients with changes in the following liver function tests: Any ALT or AST ≥ 5 x ULN; any AST or ALT ≥ 3 x ULN together with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (eosinophil percent or count above the ULN); Persistent ALT ≥ 3 x ULN for a period of more than 4 weeksMeasure: Liver Function Time: 28 days
Description: Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of > 500 ms.Measure: Heart Function Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports